Forge Biologics has something rare for most early-stage biotech startups: revenue from customers. Now it has $40 million to expand its model, which places contract manufacturing alongside the development of its own gene therapies, the most advanced of which is being readied for tests in humans.
July 23, 2020
Forge Biologics has something rare for most early-stage biotech startups: revenue from customers. Now it has $40 million to expand its model, which places contract manufacturing alongside the development of its own gene therapies, the most advanced of which is being readied for tests in humans.
From operations in Columbus, Ohio, Forge makes gene therapies for other companies. The company was initially conceived solely as a contract manufacturer, CEO Tim Miller told Xconomy. The explosion of gene therapy research is leading to growing demand for manufacturing capabilities –much more than the industry is forecast to supply in coming years. Miller says Forge will do its part to help address those needs.
But Forge’s founders realized that the company could funnel the manufacturing revenue into the development of its own gene therapies. This model reduces the financial burden on the company and by providing it with cash to pay for R&D.
Image: iStock/Pineapple Studio
“It didn’t start that way, but we grew into it, and that’s the model that’s resonated with investors and key members that wanted to sign on,” Miller says.
The most advanced Forge program is a gene therapy for Krabbe disease, an inherited neurological disorder caused by a loss of myelin, a protective covering of the nerve cells. Krabbe disease is caused by mutations in a gene called GALC, which provides the instructions for making a key protein needed to break down fats called galactolipids. The enzyme deficiency causes lipids to build up to toxic levels in myelin, eventually leading to the death of these cells.
The most common form of Krabbe affects infants and leads to problems such as muscle weakness, difficulty eating, and delayed physical and mental development. Most babies diagnosed with Krabbe die before reaching age two.
Forge’s Krabbe gene therapy candidate, FBX-101, uses an engineered adeno-associated virus (AAV) to ferry its genetic payload into cells. Other gene therapies also use these viruses, but they have been linked to dangerous side effects, including death, says Miller, who was previously the president and CEO of New York-based cell and gene therapy developer Abeona Therapeutics.
Such side effects are an immune response to AAV, and they can be a challenge at higher doses, Miller says. Forge aims to overcome these problems by combining its Krabbe gene therapy with an umbilical cord transplant. The transplant of cord blood, which is rich in stem cells, is currently the standard of care for Krabbe patients. While the treatment has been shown to improve the symptoms of the disease and correct the enzyme deficiency in the brain, Forge says these transplants don’t fix the deficiency in the peripheral nervous system.
The company hopes that combining a cord blood transplant with the gene therapy will overcome that shortcoming. Miller adds that the cord blood effectively replaces the infant’s immune system with one that does not react adversely to the gene therapy. This combination approach was pioneered by Maria Escolar, a pediatrician and Krabbe disease expert at the University of Pittsburgh. She has joined Forge as its chief medical officer.
According to preclinical research published in 2011 in The Journal of Neuroscience, the combination of a bone marrow transplant and gene therapy helped on several measures, including motor function, life span, and body weight compared to the gene therapy alone. Scientists also reported an improvement in the formation of myelin on nerve cells. The research also revealed potential risks and side effects, such as tremors. The paper says that those tremors are most likely due to the radiation treatment used to condition the body for the bone marrow transplant.
Miller says Forge’s combination approach is a platform technology that the company can apply to other gene therapies. It has two additional gene therapies in the pipeline that Miller isn’t yet ready to discuss. But he adds that a different combination – Forge’s pairing of contract manufacturing with R&D – enables Forge to finance work on multiple gene therapies.
Forge is preparing to test the combination Krabbe treatment in a clinical trial expected to start later this year. The new capital will support that research, as well as the expansion of Forge’s manufacturing capabilities. Miller says the 175,000-square-foot site is about 10 years old; Forge has occupied it for six months. The startup currently has capacity to do contract manufacturing for toxicology and preclinical testing. It’s building additional clean rooms to handle manufacturing according to cGMP standards, which Miller expects will be ready by the middle of next year. Miller says Forge will handle manufacturing work for a wide range of clients: non-profit groups, academic labs, small biotechs, and even large pharmaceutical companies. Eventually, he says the site will have the capacity to handle commercial-scale manufacturing.
Forge isn’t the only company trying to address gene therapy manufacturing needs. Last year, Waltham MA-based ElevateBio raised $150 million in financing to back its plans for a contract manufacturing facility. The company also invests in cell and gene therapy startups.
In January, Nationwide Children’s Hospital formed Andelyn Biosciences, a contract gene therapy manufacturer. Though Andelyn is a for-profit company, Nationwide Children’s, a hub of gene therapy R&D, says the startup’s revenue will be reinvested in the hospital’s Abigail Wexner Research Institute. Though Forge is also headquartered in Columbus, the company has no affiliation with Nationwide Children’s. But Miller says that the emergence of gene therapy startups in the region makes it a good place to set up shop.
“Ohio, and Columbus in particular, is becoming a hot bed of biotech development,” Miller says.
The Forge financing was led by Perceptive Xontogeny Venture Fund (PXV), with additional participation from Drive Capital. Chris Garabedian, manager of the PXV fund, said in an email that he sees Forge as offering “beautiful synergies” for the manufacturing and development of gene therapies. Garabedian, who is joining Forge’s board as chairman, also sees the company’s model as the source of potential alliances involving Xontogeny, a startup accelerator he also leads, or financing from PXV Fund.
You May Also Like
